Guardion Health Sciences, Inc GHSI shares are trading higher after the company announced it received a patent from the Patents Registry in Hong Kong for its proprietary medical device, the MapcatSF.
The MapcatSF measures the macular pigment density in the human eye, thus facilitating treatment for several ocular conditions and diseases that affect a large number of patients.
“The granting of this patent in Hong Kong represents an important step in Guardion’s process to expand into the large Asian markets, where evidenced-based eye care is of great interest to both physicians and consumers,” says David Evans, Guardion’s chief science officer in a statement.
Guardion Health Sciences traded higher by 148% to $2.37 at time of publication.
Related Links:
Ohr Pharmaceutical Merger With Neubase Therapeutics Approved By Shareholders
CareTrust REIT Buys A Skilled Nursing Facility In Idaho For $12.8M
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.